|Articles|January 28, 2022

AJMC® in the Press, January 28, 2022

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by Becker's Hospital Review cited a study published in the January 2022 Health Information Technology (IT) special issue of The American Journal of Managed Care^®(AJMC^®). The study, “Understanding Physicians’ Work via Text Analytics on EHR Inbox Messages,” leveraged text analytics to identify work themes managed by primary care physicians in their electronic health record inbox messages and inform managers on workflow redesign. The study was also mentioned in a piece by EHRIntelligence.

A piece by mHealthIntelligence referenced another study published in the January 2022 Health IT special issue of AJMC^®, titled “Addressing Virtual Care Disparities for Patients With Limited English Proficiency.” The study provided recommendations that address disparities for patients with limited English proficiency following the increase in use of virtual care due to the COVID-19 pandemic.

A study published online ahead of print from the July 2022 issue of AJMC^®, titled “Projected US Savings From Biosimilars, 2021-2025,” was spotlighted in an article by HealthDay. Findings of the study indicated that projected savings from biosimilars from 2021 to 2025 were $38.4 billion vs conditions as of quarter 4 of 2020 and were driven by new biosimilar entry.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related to this article

October 2nd, 2026

Building a Scalable Obesity Care Team: Amanda Velazquez, MD

Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.

Sjogren's Syndrome text with Medical Stethoscope on wooden background | Image credit may1985 - stock.adobe.com

October 2nd, 2026

Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Women using an inhaler. | Image credit: @Antonioguillem.jpeg

September 30th, 2026

FDA Accepts Inhaled Treprostinil sNDA for IPF: 4 FAQs for Payers

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

CAR T-cell Image | Image Credit: © Love Employee-stock.adobe.com

September 30th, 2026

Payers and Providers Map the Path to Community CAR T Access

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.